The digital therapeutics industry, encompassing prescription software that aim to treat specific conditions, is continuing to expand. Investors and healthcare stakeholders are beginning to take notice. In December, Pear Therapeutics became one of the first digital therapeutics companies to go public.
However, there are still many questions around the usability and scalability of these products....
A new digital/pharma partnership. Amid a breakdown of its new strategic direction, Paris-based Voluntis announced a new partnership with Bristol-Myers Squibb that aims to support cancer patients with a new digital-therapeutic platform. Patients would use this app-based tool to track their symptoms and treatment, while also being provided with relevant self-management recommendations via an...
Paris, France-based Voluntis has received FDA marketing authorization for an algorithm-driven digital tool that helps cancer patients manage their symptoms and care teams identify clinical insights, the company announced last week.
The Oleena software is a Class II medical device that is prescribed by the patient’s care team. As the user logs their symptoms into the app, it adapts to offer...
Clinical research software company Elligo Health Research has entered a partnership with HealthiVibe, a company that collects patient insights in order to improve clinical trials. As part of the new deal Elligo will be able to offer HealthiVibe’s platform HealthiPerspectives, which collects patients' feedback about clinical trials and gathers patient data.
“Partnering with Elligo enables us to...
Digital therapeutics may be up and coming, but they also have a long way to go before their mainstream treatment options, according to experts who spoke at the digital therapeutics deep dive at HIMSS18.
“This is going to be a completely new industry sector,” Pierre Leurent, CEO of Voluntis, said during the session. “It’s going to have very strong growth in the years to come and it’s going to be a...
Correction: A previous version of this story mistated the projected timeline for the combined product. It is Q1 this year, not Q1 next year.
WellDoc and Voluntis, two companies with FDA-cleared, clinically validated platforms aimed at the management of Type 2 diabetes, have signed a commercial agreement to combine their technologies and offer joint products in the future.
“My thought is that a...
A slew of digital diabetes care companies have announced integrations with the upcoming virtual Type 2 diabetes management platform being developed by Onduo, a joint venture of Verily and Sanofi. These announced services include Voluntis’ Insulia, a digital insulin dose recommendation and coaching system; Glytec’s Glucommander Outpatient, cloud-based software that evaluates blood glucose and...
Medical device software company Voluntis has received an updated FDA clearance (as well as an updated CE mark) for its Insulia app, a "digital companion" app for people with Type 2 diabetes. Insulia offers realtime basal insulin dose coaching, and the new clearance makes the app usable with two additional brands of insulin: Basaglar and Tresiba. The app had already worked for users of Lantus,...
A group of health startups in the burgeoning digital therapeutics space have joined together to create a new industry association, the Digital Therapeutics Alliance (DTA).
“Digital therapeutics are re-writing our definition of medicine,” Akili Interactive CEO Eddie Martucci said in a statement. “It’s critical that industry, academia, government, and the medical community work together in the...
Diabetes management is a focus area for a number of digital health companies, and increasingly large medical device companies like Medtronic and Dexcom are turning to smartphone apps and connected devices for their consumer offerings. So it’s no surprise that at the 77th Scientific Sessions of the American Diabetes Association, which start today, there is a significant health tech presence.
We...
.jpeg?itok=HF3iI7dj "Person answering their front door and getting a delivery from another person")
_11.JPG?itok=zvOssCR2)
